Contributor: Special thanks to Stuart Head from the Task Force on Myocardial Revascularization of ESC and EACTS, with contribution of EAPCI.
Based on the 2014 ESC/EACTS Guidelines in Myocardial Revascularisation.
Webinars on this topic
2016 ESC General Cardiology webinar, "Myocardial revascularization : how have the guidelines changed our practice" Watch the recording.
2015 ESC General Cardiology webinar, the multidiscplinary heart team discussions on "Diabetic patient with stable angina" Watch the recording.
Part 1 - Overview of the 2014 ESC/EACTS Guidelines on Myocardial Revascularization
| Session |
Presentation |
Slides |
Webcast |
| ESC 2014 Guidelines overview |
Myocardial revascularization |
|
|
ESC/EACTS Guidelines on Myocardial Revasularization
|
Strength of a joint ESC/EACTS Task Force |
|
|
| Risk assessment and patient information |
|
|
| Revascularization in patients with stable coronary artery disease |
|
|
| Revascularization in patients with coronary artery disease and associated conditions |
|
|
Antithrombotic therapy in patients undergoing revascularization |
|
|
| Take home messages for practitioners |
Concluding remarks |
|
|
| Coronary artery disease update 2014 |
|
|
Meet the Guidelines
Task Force I |
Myocardial revascularization |
|
|
Part 2: Topics in focus
| Topic |
Session Title |
Slides |
Webcast |
| IMAGING |
Optimal non-invasive strategy to detect worsening and severe ischaemia |
|
|
| High risk patients with stable angina. When coronary angiography should be the first choice |
|
|
| SCAD |
Coronary artery bypass surgery is the best option |
|
|
| A fractional flow reserve-guided PCI is a valid alternative |
|
|
| Left main disease: the surgeon's view |
|
|
| How to individualise the revascularisation treatment? |
|
|
| Fractional flow reserve-guided PCI versus medical treatment in stable coronary disease: FAME 2 primary end-point data analysis |
|
|
NSTE-ACS |
Revascularization in high risk NSTEMI |
|
|
| NSTEMI: cath lab now or later? |
|
|
| STEMI |
Is there (still) a role for thrombectomy in STEMI |
|
|
| STEMI: essential questions in primary PCI |
|
|
| CARDIOGENIC SHOCK |
Primary PCI: culprit lesion or immediate complete reveascularization? |
|
|
| Percutaneous support: when and how |
|
|
| DIABETES |
Revascularization in diabetes patients: CABG versus PCI |
|
|
| VALVE INTERVENTIONS |
More aortic stenosis than coronary artery disease |
|
|
| Combined aortic stenosis and coronary artery disease: conclusions and general take home message |
|
|
| REPEAT PROCEDURES |
Stent thrombosis and restenosis: what have we learned and where are we going? |
|
|
| PCI |
Optical coherence tomography: just nice to have or mandatory? |
|
|
| ANTITHROMBOTIC |
When to stop dual antiplatelet therapy after ACS - less is more? |
|
|
| Early initiation of antiplatelet therapy - Recommendations and current practice |
|
|
| Upstream versus intraprocedural antiplatelet therapy |
|
|
| Pre-treatment with P2Y12 inhibitors in acute coronary syndrome. PRO and CONTRA |
|
|
| Complete versus Lesion only Primary-PCI Trial (CvLPRIT): treat the infarct related artery only or all lesions. |
|
|
| Bivalirudin as anticoagulant in primary PCI - pros and cons |
|
|
Our mission: To reduce the burden of cardiovascular disease.